Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
Brandi G, Relli V, Deserti M, Palloni A, Indio V, Astolfi A, Serravalle S, Mattiaccio A, Vasuri F, Malvi D, Deiana C, Pantaleo MA, Cescon M, Rizzo A, Katoh M, Tavolari S.
Brandi G, et al. Among authors: deiana c.
Sci Rep. 2024 Feb 7;14(1):3136. doi: 10.1038/s41598-024-52991-8.
Sci Rep. 2024.
PMID: 38326380
Free PMC article.